No Data
No Data
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Announces Target Price $163
Wells Fargo analyst Larry Biegelsen maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and sets the target price at $163.According to TipRanks data, the analyst has a success rate of 58.5% and
Weekend Reading | How Johnson & Johnson Orthopedics' Empire Dream Was Shattered?
The opportunity for the pharmaceutical industry to explode must be hidden in the unmet clinical needs, which are the directions that pharmaceutical companies need to continue to cultivate.
Unusual Options Activity: JNJ, CSCO and Others Attract Market Bets, JNJ V/OI Ratio Reaches 153.8
EST Jul 5th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
What's Going On With Johnson and Johnson Shares Friday?
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
ohnson & Johnson’s (JNJ Quick QuoteJNJ - Free Report) stock has been trading below its 200-day and 50-day moving averages since the end of June. On Jul 3, the stock’s closing price of $145.69 was below its 50-day moving average of $147.61 and the 200-day moving average of 151.95.
Johnson & Johnson's bispecific antibody drug talquetamab has been approved for sale in South Korea.
On July 2, Johnson & Johnson's (JNJ.US) South Korea company announced that its bispecific antibody drug Talquetamab has been approved for launch in South Korea.